Interleukin-11 to Enter Phase III

July 1, 1995

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 4 No 7

Volume 4

Issue 7

CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinant human interleukin-11 (rhIL-11) restored platelets in throm-bocytopenic patients undergoing cancer chemotherapy to the extent that significantly fewer rhIL-11 treated patients required platelet transfusions, compared to placebo.

CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinanthuman interleukin-11 (rhIL-11) restored platelets in throm-bocytopenicpatients undergoing cancer chemotherapy to the extent that significantlyfewer rhIL-11 treated patients required platelet transfusions,compared to placebo.

Based on this favorable outcome, the company plans to begin aphase III study by the end of this year.

Articles in this issue

ODAC Recommends Accelerated FDA Approval of Ethyol for Cytoprotection

House Panel Holds Hearing on Self-Referral

Health-Related Legislation

Mitoguazone Appears Promising in HIV-Associated Refractory NHL

Responses to Anti-HER2 MoAb Seen

NCI Committed to Increasing Minority Participation in Clinical Trials

MoAb May Improve Detection of Colon And Rectal Cancer

Zeneca Files NDA for Arimidex

Cord Blood is Used as Source of Stem Cells for Pediatric Transplantation

Gemcitabine/Cisplatin Shows Good Response Rate And Favorable Toxicity Profile in Advanced NSCLC

HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and Abuse

M.D. Anderson Holds First Cancer Meeting in Spanish

Molecular Markers Predict Clinical Outcome

NCAB Has Concerns About Future of Clinical Research

IP Interleukin-2 Shows Durable Responses in Ovarian Cancer

Recent Videos

“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.

2 experts are featured in this series.

4 experts in this video

Related Content

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

The B7-H3-low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.

Nivolumab Plus Relatlimab Show Long-Term EFS Benefit in Advanced Melanoma

The B7-H3-low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.

Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

$A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.$

Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma

A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

Data from the phase 3 BEACON CRC trial support the approval of encorafenib plus cetuximab for this colorectal cancer population in China.

Encorafenib Combo Earns Chinese Approval in BRAF V600E+ Metastatic CRC

Data from the phase 3 BEACON CRC trial support the approval of encorafenib plus cetuximab for this colorectal cancer population in China.

Related Content

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

The B7-H3-low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.

Nivolumab Plus Relatlimab Show Long-Term EFS Benefit in Advanced Melanoma

The B7-H3-low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.

Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

$A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.$

Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma

A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

Data from the phase 3 BEACON CRC trial support the approval of encorafenib plus cetuximab for this colorectal cancer population in China.

Encorafenib Combo Earns Chinese Approval in BRAF V600E+ Metastatic CRC

Data from the phase 3 BEACON CRC trial support the approval of encorafenib plus cetuximab for this colorectal cancer population in China.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.